Saturday 17 October 2026 Export BPTH’s income statement to Excel — free account

Bio-Path Holdings, Inc.

In the quarter to March 2026, EPS fell 101.2% and free cash flow grew 98.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.00 0.00 NaN

Follow BPTH

Alert me

Market cap: $1.1M
P/E: 0.0×
Fwd P/E: −0.2×
Dividend yield: —
F-score: n/a
Altman Z: 6.86
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 64.68%

Capital & Financial Ratios $m

Market Cap 1.07

Revenue —

Net Income 2.58

Free Cash Flow (1.63)

Net Debt (0.01)

Current Ratio 0.07

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.24)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 99.53%

Next Y EPS Growth 51.10%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 64.69%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	Q'26
Cash	10	1	1	0
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	2	1	2	0
	16	3	4	1

	2022	2023	2024	Q'26
Payables	1	0	1	5
ST’ Debt	—	—	—	—
Other	—	—	—	0
	2	2	3	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(36.70%)	(62.61%)	(81.78%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’17	—	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	0	—	—
’24	(1)	(3)	(3)	(3)	(11)
’23	(4)	(3)	(3)	(2)	(12)
’22	(3)	(4)	(3)	(5)	(15)
’21	(2)	(3)	(3)	(3)	(10)
’20	(3)	(3)	(2)	(3)	(11)
’19	(2)	(2)	(2)	(2)	(8)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	0	—	—
’24	(1)	(3)	(3)	(3)	(11)
’23	(4)	(3)	(3)	(2)	(12)
’22	(3)	(4)	(3)	(5)	(15)
’21	(2)	(3)	(3)	(3)	(10)
’20	(3)	(3)	(2)	(3)	(11)
’19	(2)	(2)	(2)	(2)	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.40)	(0.55)	(0.11)	—	—
’24	(4.88)	(1.16)	(0.70)	2.62	(4.12)
’23	(13.20)	(10.60)	(6.40)	(3.39)	(33.63)
’22	(9.40)	(8.40)	(9.80)	(10.60)	(38.20)
’21	(8.60)	(5.20)	(5.80)	(11.80)	(31.00)
’20	(18.00)	(11.00)	(16.00)	(11.40)	(56.60)
’19	(17.80)	(17.40)	(15.60)	(14.40)	(64.80)

Fiscal quarters ending in the months shown.

Group	Line	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
Price, $
Price, $	Low	—	3,800.00	725.20	60.00	32.20	58.41	69.97	25.46	6.40	0.59	Analyst estimates 2025–2027 Powerpack
	High	—	12,760.00	5,400.00	1,236.00	1,470.40	169.80	486.80	89.57	47.00	12.00
People
People	Employees	—	12	9	8	9	10	10	10	10	10
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	0	0	—	—	—	—	—	—	—
	Gross margin, %	—	100.00	100.00	0.00	0.00	0.00	0.00	0.00	—	—
	EBT	—	(7)	(7)	(9)	(9)	(11)	(10)	(14)	(16)	(10)
	EBT margin, %	—	(51,923.08)	(18,981.08)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	(7)	(7)	(9)	(9)	(11)	(10)	(14)	(16)	(10)
	Depreciation	—	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	0.56	1.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	(280.00)	(320.00)	(287.60)	(64.80)	(56.60)	(31.00)	(38.20)	(33.63)	(4.12)
	Cash flow	—	(351.21)	(315.75)	(204.82)	(62.91)	(56.96)	(29.49)	(41.49)	(24.13)	(4.40)
	Capex	—	(14.57)	(21.35)	(0.57)	0.00	0.00	(0.21)	(0.06)	0.00	0.00
	Free cash flow	—	(365.78)	(337.10)	(205.38)	(62.91)	(56.96)	(29.70)	(41.55)	(24.13)	(4.40)
	Book value	—	355.17	320.12	40.74	158.66	78.33	75.70	38.94	0.92	0.06
	Shares, m	—	0	0	0	0	0	0	0	0	2
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	—	—	—	—	—	—	—
	P/S	—	0.00	0.00	—	—	—	—	—	—	—
	P/B	—	14.08	2.62	—	—	—	—	—	—	—
	EV/Sales	—	0.00	0.00	—	—	—	—	—	—	—
	EV/FCF	—	(12.39)	(1.79)	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	(8)	(8)	(6)	(8)	(11)	(10)	(15)	(12)	(11)
	Capex	—	0	(1)	0	—	—	0	0	—	—
	Free cash flow	—	(8)	(8)	(6)	(8)	(11)	(10)	(15)	(12)	(11)
Balance, $m
Balance, $m	Working capital	—	10	7	1	21	15	25	14	1	0
	Total debt	—	—	—	—	0	0	0	0	—	—
	Net debt	—	(9)	(6)	(1)	(20)	(14)	(24)	(10)	(1)	(1)
	Shareholders’ equity	—	8	8	1	21	15	25	14	0	0
Returns, %
Returns, %	ROA	—	(58.82)	(76.57)	(150.54)	(68.23)	(55.61)	(48.51)	(65.20)	(167.56)	(278.59)
	ROIC	—	0.00	(266.59)	(2,508.76)	(823.20)	(518.44)	(387.81)	(229.24)	0.00	0.00
	ROE	—	(74.76)	(98.87)	(184.88)	(77.11)	(60.19)	(51.52)	(69.99)	(220.02)	(3,325.71)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2017

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PTIX Atrinsic Inc.	$1.3M	0.3×	—	+34.31% (above 0%: growing)	n/m	+46.07% (above 0%: growing)	0.00%	0.00%	Compare
SPRC SciSparc Ltd.	$1.2M	— (loss-making)	7.9×	—	n/m	+14.95% (above 0%: growing)	35.75%	0.00%	Compare
CYTOF Altamira Therapeutics Ltd.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+85.35% (above 0%: growing)	(157.79%)	0.00%	Compare
BPTH Bio-Path Holdings, Inc.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+98.68% (above 0%: growing)	0.00%	0.00%
BBLG Bone Biologics Corp.	$1.1M	— (loss-making)	—	—	n/m	−12.97% (below 0%: shrinking)	—	0.00%	Compare
CRIS Curis, Inc.	$1.1M	— (loss-making)	— (loss-making)	−65.98% (below 0%: shrinking)	n/m	−20.44% (below 0%: shrinking)	100.00%	0.00%	Compare
MNTRQ 9 Meters Biopharma, Inc.	$1.0M	— (loss-making)	—	−25.99% (below 0%: shrinking)	n/m	+0.01% (above 0%: growing)	0.00%	0.00%	Compare
ZVSA ZyVersa Therapeutics, Inc.	$970.0K	— (loss-making)	—	—	n/m	+54.91% (above 0%: growing)	0.00%	0.00%	Compare
LYRA Lyra Therapeutics, Inc.	$870.0K	— (loss-making)	— (loss-making)	−96.65% (below 0%: shrinking)	n/m	+45.44% (above 0%: growing)	100.00%	(101,685.71%)	Compare
Median of peers	$1.1M	—	—	−45.99%	—	+30.20%	0.00%	0.00%

All 614 Biotechnology stocks →